Jin Lab: Research Update Stabilized Immunoliposomes for Targeted Drug Delivery Nwanyinma Nnodum

Background 1 – Traditional “plain” nanocarrier (a – drug loaded into carrier) 2 – Targeted nanocarrier or immunocarrier (b – mAb attached to carrier surface) 3 – Magnetic nanocarrier (c – magnetic particles loaded into carrier together with the drug) 4 – Long-circulating nanocarrier (d – surface-attached protecting polymer (usually PEG)) 5 – Contrast imaging nanocarrier (e – heavy metal atom (i.e. 111In) loaded onto the nanocarrier via the carrier-incorporated chelating moiety) 6 – Cell-penetrating nanocarrier (f – cell-penetrating peptide, CPP, attached to the carrier surface) 7 – DNA-carrying nanocarrier (g – DNA complexed by the carrier via the carrier surface positive charge) 8 –Multifunctional pharmaceutical nanocarrier combining the properties of the carriers # 1–7. Potential of Liposomes as Pharmaceutical Nanocarriers

Background 1 – Traditional “plain” nanocarrier (a – drug loaded into carrier) 2 – Targeted nanocarrier or immunocarrier (b – mAb attached to carrier surface) 3 – Magnetic nanocarrier (c – magnetic particles loaded into carrier together with the drug) 4 – Long-circulating nanocarrier (d – surface-attached protecting polymer (usually PEG)) 5 – Contrast imaging nanocarrier (e – heavy metal atom (i.e. 111In) loaded onto the nanocarrier via the carrier-incorporated chelating moiety) 6 – Cell-penetrating nanocarrier (f – cell-penetrating peptide, CPP, attached to the carrier surface) 7 – DNA-carrying nanocarrier (g – DNA complexed by the carrier via the carrier surface positive charge) 8 –Multifunctional pharmaceutical nanocarrier combining the properties of the carriers # 1–7. Potential of Liposomes as Pharmaceutical Nanocarriers

Overview FITC Encapsulation Floatation assay Cell Culture HeLa: human cervical cancer cells MDA-MB231: human breast cancer cells MCF-7: human breast cancer cells NIH 3T3: mouse fibroblast cells FACS MAP-wGFP-His 9R-wGFP-His RGD HER2 Protein Expression & Purification

Methods FITC Encapsuation FITC encapsulated during lipid hydration step (0.48 mg FITC/mL HBS) Floatation assays using sucrose Mix 500 µ L sample µ L 70% sucrose Gently add 3mL of 20% sucrose to top Ultracentrifuge for 2hrs at rpm, 8°C Remove band (liposome + FITC) at top with 16g syringe & rest is free FITC Bring fractions to 4mL & check absorbance with Nanodrop Cell Culture alphaMEM+10%FBS+1%PenStrep for MDA-MB231, MCF-7, NIH-3T3 Advanced DMEM +10%FBS+1%Glutamine for HeLa

Methods (cont.) Flow Cytometry (FACS) Sample Prep Spin down cells from tissue culture & remove supernatant Resuspend in 1xPBS Aliquot 100µL per sample, spin down, & remove sup. Resuspend in 100µL of PBS+1%BSA+protein sample Incubate for 1hr at 4°C Spin down & remove sup. with free protein Resuspend in 200µL of PBS+1%BSA X-wGFP Synthesis & Purification Large scale production of MAP-, 9R-, wGFP Purification with Ni-NTA-His column, SDS-PAGE, FPLC

Results FITC Encapsulation Absorbtion495nm Sample 1Sample 2 Original Abs average Free FITC Abs average FITC+Liposome Abs average Efficiency (%Encapsulated) Efficiency (%Free) volume (mL)0.5 Original Conc (mg/mL) mg FITC encapsulated (mg) Less than 5% encapsulated

Results (cont.) Flow Cytometry (FACS) HeLA NIH-3T3

Results (cont.) Flow Cytometry (FACS) Noise! Minimal shift Incubation at 37°C More cells MDA-MB231 MCF-7

Future Plans FACS With proteins With proteins plus liposomes Confocal microscopy Drug encapsulation

References Peer, Park, Morishita, Carman, Shimaoka. “Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target”. Science. 319(2008): Ronny Ruger, Dafne Muller, Alfred Fahr, & Roland E. Kontermann. “In Vitro Characterization of Binding and Stability of Single-Chain Fv Ni-NTA-Liposomes”. Journal of Drug Targeting (2006): 576–582.

Thanks for listening!